Full Press Release Details
Tailored Novel Cancer Vaccines Based upon a New Untapped Source of AI-Discovered Targets
COPENHAGEN, Denmark,
Jan. 24, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) ("Evaxion" or the "Company"), a clinical-stage
TechBio company specializing in developing AI-Immunology powered vaccines, announces an expanded commitment to developing tailored
cancer vaccines by targeting a novel category of AI-identified tumor antigens, named Endogenous Retroviruses (ERVs).
opportunity may broaden the applicability of cancer vaccines. Through the new vaccine targets, ERVs, treating patients unresponsive to
conventional cancer immunotherapy may become possible. With the elevated focus on this groundbreaking therapeutic concept, Evaxion has
initiated preclinical activities with a goal of generating Proof-of-Concept data by the second half of 2024.
Chief Scientific Officer, Birgitte R n , expresses optimism, "With our intensified focus on ERV cancer vaccines,
we aim to expedite the development process to deliver treatment solutions to cancer patients who, until now, have been deemed unresponsive
to immunotherapy. The ERV cancer vaccine targets represent a promising breakthrough that could significantly broaden the horizons of
cancer vaccine applicability and marks a significant step forward in our commitment to improving healthcare through innovative and AI-powered
approaches. We are already seeing significant interest in ERV-based vaccines and look forward to further underpinning the significant
potential by these Proof-of-Concept data."
into these exciting opportunities were presented by Evaxion at the last American Society of Hematology (ASH) Annual Meeting. For further
information, please see our previous press release.
of ancient viruses lying dormant in our genome. ERVs are often overexpressed in cancer but not in healthy tissue, making them visible
to the immune system and hence promising targets for cancer vaccines. AI-Immunology is crucial in allowing the identification
of therapeutically relevant ERV tumor antigens from genomic patient tumor data.
is a scalable and adaptable artificial intelligence technology platform at the forefront of vaccine discovery for infectious diseases
and cancers. By integrating the collective power of proprietary AI models PIONEER , EDEN , RAVEN , and ObsERV ,
the platform can model the complexity of the patient's immune system. AI-Immunology advanced computational modeling swiftly and
uniquely identifies, predicts, and designs vaccine candidates, revolutionizing the landscape of immunotherapy by offering a holistic
and personalized approach to combat fast-evolving pathogens and malignant cells.
A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology . Evaxion's proprietary and scalable AI prediction
models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial
diseases, and viral infections. Based upon AI-Immunology , Evaxion has developed a clinical-stage oncology pipeline of novel personalized
vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed
to transforming patients' lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking
AI-Immunology platform and vaccine pipeline, please visit our website.
contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E
of the Securities Exchange Act of 1934, as amended. The words "target," "believe," "expect," "hope,"
"aim," "intend," "may," "might," "anticipate," "contemplate," "continue,"
"estimate," "plan," "potential," "predict," "project," "will," "can
have," "likely," "should," "would," "could," and other words and terms of similar meaning
identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as
a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital;
our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any
approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our
product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability
to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth;
our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including
inflation, and the effects on our business from the worldwide ongoing COVID-19 pandemic and the ongoing conflict in the region surrounding
Ukraine and Russia and the Middle East; and other uncertainties affecting our business operations and financial condition. For a further
discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings
with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation
to update any forward-looking statements except as required by law.